Clinical Trial Update: A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

This report covers the completion of a Phase 1 safety confirmatory study of alemtuzumab in Japanese patients with relapsed or refractory chronic lymphocytic leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Status: COMPLETED